Report Detail

Pharma & Healthcare Fibromyalgia – Pipeline Insight, 2020

  • RnM3882670
  • |
  • 05 November, 2020
  • |
  • Global
  • |
  • 150 Pages
  • |
  • DelveInsight
  • |
  • Pharma & Healthcare

DelveInsight’s, “Fibromyalgia – Pipeline Insight, 2020,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Fibromyalgia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Fibromyalgia Understanding
Fibromyalgia: Overview
Fibromyalgia is a common neurologic health problem that causes widespread pain and tenderness (sensitivity to touch). The pain and tenderness tend to come and go, and move about the body. Most often, people with this chronic (long-term) illness are fatigued (very tired) and have sleep problems. The diagnosis can be made with a careful examination. Fibromyalgia is most common in women, though it can occur in men. It most often starts in middle adulthood, but can occur in the teen years and in old age.
Symptoms
The symptoms of fibromyalgia include:
• fatigue
• trouble sleeping
• sleeping for long periods of time without feeling rested (nonrestorative sleep)
• headaches
• depression
• anxiety
• trouble focusing or paying attention
• pain or a dull ache in the lower belly
• dry eyes
• bladder problems, such as interstitial cystitis
Diagnosis
Although fibromyalgia is the most common chronic widespread pain condition, it is often under diagnosed. The diagnosis of fibromyalgia has been shown to increase patient satisfaction and reduce healthcare utilization. The assessment of Fibromyalgia is based on the criteria for the Classification of Fibromyalgia by the American College of Rheumatology, (ACR) 1990. The criterion involves:
History of widespread pain has been present for at least three months.
Pain in both sides of the body pain above and below the waist. Pain is considered widespread when all of the following are present:
Pain in 11 of 18 tender point sites on digital palpation (both side of the body): Occiput (2),Low cervical (2),Trapezius (2), Supraspinatus (2), Second rib (2), Lateral epicondyle (2), Gluteal (2), Greater trochanter (2), Knee (2).
Treatment
There are different pain medications which are useful in the management of FMS. Paracetamol, NSAIDs have been used but pain usually do not respond to them. Acetaminophen may ease the pain and stiffness caused by fibromyalgia. Besides analgesics, there are drugs used like antidepressant, anti convulsant, Dopamine agonist and Growth hormone.
Fibromyalgia Emerging Drugs Chapters
This segment of the Fibromyalgia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Fibromyalgia Emerging Drugs
• NYX-2925: Aptinyx
NYX-2925 is a novel, oral small molecule NMDA receptor modulator in development for the treatment of Fibromyalgia.
Further product details are provided in the report……..
Fibromyalgia: Therapeutic Assessment
This segment of the report provides insights about the different Fibromyalgia drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Fibromyalgia
There are approx. 50+ key companies which are developing the therapies for Fibromyalgia. The companies which have their Fibromyalgia drug candidates in the most advanced stage, i.e. phase II include, Aptinyx.
• Phases
DelveInsight’s report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Fibromyalgia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Fibromyalgia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Fibromyalgia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fibromyalgia drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Fibromyalgia R&D. The therapies under development are focused on novel approaches to treat/improve Fibromyalgia.
Fibromyalgia Report Insights
• Fibromyalgia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Fibromyalgia Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Fibromyalgia drugs?
• How many Fibromyalgia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Fibromyalgia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Fibromyalgia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Fibromyalgia and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Eli Lilly and Company
• UCB Pharma
• Tonix Pharmaceuticals, Inc.
• Theravance Biopharma
• Teva Pharmaceutical Industries
• Sosei
• Sanofi
• RiboCor, Inc.
• Jazz Pharmaceuticals
• Ipsen
• Innovative Med Concepts, LLC
• IgNova GmbH
• GlaxoSmithKline
• Chelsea Therapeutics
• Cephalon
• Capnia, Inc.
• Astellas Pharma
• Aptinyx
Key Products
• Desvenlafaxine Sustained Release
• Nabilone
• Duloxetine
• Rotigotine
• TNX-102
• TD-9855
• Fremanezumab
• Ibuprofen
• AD 337
• D-Ribose
• XyremÂ
• Botulinum toxin type A
• IMC-1
• IGN-ES001
• ropinirole
• Droxidopa
• OraVescent Fentanyl
• ESL 400
• Ibutamoren Mesylate (MK-0677)
• ASP8062
• ASP0819
• NYX-2925


Introduction

    Executive Summary

      Fibromyalgia: Overview

        • Causes

          • Mechanism of Action

            • Signs and Symptoms

              • Diagnosis

                • Disease Management

                  Pipeline Therapeutics

                    • Comparative Analysis

                      Therapeutic Assessment

                        • Assessment by Product Type

                          • Assessment by Stage and Product Type

                            • Assessment by Route of Administration

                              • Assessment by Stage and Route of Administration

                                • Assessment by Molecule Type

                                  • Assessment by Stage and Molecule Type

                                    Fibromyalgia – DelveInsight’s Analytical Perspective

                                      In-depth Commercial Assessment

                                        • Fibromyalgia companies’ collaborations, Licensing, Acquisition -Deal Value Trends

                                          Fibromyalgia Collaboration Deals

                                            • Company-Company Collaborations (Licensing / Partnering) Analysis

                                              • Company-University Collaborations (Licensing / Partnering) Analysis

                                                Late Stage Products (Phase III)

                                                  • Comparative Analysis

                                                    Cyclobenzaprine hydrochloride very low dose - Tonix Pharmaceuticals

                                                      • Product Description

                                                        • Research and Development

                                                          • Product Development Activities

                                                            Drug profiles in the detailed report…..

                                                              Mid Stage Products (Phase II)

                                                                • Comparative Analysis

                                                                  NYX-2925: Aptinyx

                                                                    • Product Description

                                                                      • Research and Development

                                                                        • Product Development Activities

                                                                          Drug profiles in the detailed report…..

                                                                            Early Stage Products (Phase I)

                                                                              • Comparative Analysis

                                                                                TD-9855: Theravance Biopharma

                                                                                  • Product Description

                                                                                    • Research and Development

                                                                                      • Product Development Activities

                                                                                        Drug profiles in the detailed report…..

                                                                                          Pre-clinical and Discovery Stage Products

                                                                                            • Comparative Analysis

                                                                                              Drug Name: Company Name

                                                                                                • Product Description

                                                                                                  • Research and Development

                                                                                                    • Product Development Activities

                                                                                                      Drug profiles in the detailed report…..

                                                                                                        Inactive Products

                                                                                                          • Comparative Analysis

                                                                                                            Fibromyalgia Key Companies

                                                                                                              Fibromyalgia Key Products

                                                                                                                Fibromyalgia- Unmet Needs

                                                                                                                  Fibromyalgia- Market Drivers and Barriers

                                                                                                                    Fibromyalgia- Future Perspectives and Conclusion

                                                                                                                      Fibromyalgia Analyst Views

                                                                                                                        Fibromyalgia Key Companies

                                                                                                                          Appendix

                                                                                                                          Summary:
                                                                                                                          Get latest Market Research Reports on Fibromyalgia. Industry analysis & Market Report on Fibromyalgia is a syndicated market report, published as Fibromyalgia – Pipeline Insight, 2020. It is complete Research Study and Industry Analysis of Fibromyalgia market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                          Last updated on

                                                                                                                          REPORT YOU MIGHT BE INTERESTED

                                                                                                                          Purchase this Report

                                                                                                                          $2,500.00
                                                                                                                          $5,000.00
                                                                                                                          $7,500.00
                                                                                                                          1,980.00
                                                                                                                          3,960.00
                                                                                                                          5,940.00
                                                                                                                          2,310.00
                                                                                                                          4,620.00
                                                                                                                          6,930.00
                                                                                                                          378,225.00
                                                                                                                          756,450.00
                                                                                                                          1,134,675.00
                                                                                                                          208,425.00
                                                                                                                          416,850.00
                                                                                                                          625,275.00
                                                                                                                          Credit card Logo

                                                                                                                          Related Reports


                                                                                                                          Reason to Buy

                                                                                                                          Request for Sample of this report